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Background: Active, ligand-mediated, targeting of functionalized liposomes to folate receptors 
(FRs) overexpressed on cancer cells could potentially improve drug delivery and specificity. 
Studies on folate-targeting liposomes (FTLs) have, however, yielded varying results and gener-
ally fail to display a clear benefit of FR targeting.
Method: Tumor accumulating potential of FTLs and NTLs were investigated in a FR overex-
pressing xenograft model by positron emission tomography/computed tomography imaging.
Results: Tumors displayed significantly lower activity of FTLs than NTLs. Furthermore, FTLs 
displayed worse circulating properties and increased liver-accumulation than NTLs. 
Conclusion: This study underlines that long-circulating properties of liposomes must be 
achieved to take advantage of EPR-dependent tumor accumulation which may be lost by func-
tionalization. FR-functionalization negatively affected both tumor accumulation and circulation 
properties.
Keywords: liposomes, folate, cancer, imaging, PET, EPR
Background
Since the first description of the enhanced penetration and retention (EPR) effect in 
solid cancers, nano-sized drug delivery systems have been the subject for extensive 
research following their passive accumulation in malignant tissue.1 Liposome-based 
drug delivery systems is the most successful EPR-dependent nano-sized drug delivery 
systems due to highly flexible and versatile nature of liposomes.2 Despite their ability 
to achieve high level of fat accumulation in the cancerous tissue, liposomal drug 
delivery systems relying on passive uncontrolled drug release mechanisms have not 
revolutionized cancer therapy. Based on this, functionalized liposomes, which com-
bine the passive EPR accumulation with selective uptake in cancer cells displaying 
a specific cell receptor, have been subject for intense research. Several studies and 
reviews conclude and state that actively targeting liposomes can significantly increase 
the amount of drug delivered to the target cell in comparison to the free-drug and pas-
sively targeting liposomal drug delivery systems.3 Even though these statements have 
been published extensively, very limited in vivo data support them. In vitro data provide 
extensive evidence of receptor targeting liposomes being taken up actively by cancer 
cells expressing the specific surface receptor.4–6 Notwithstanding these observations, 
we speculate that the tumor microenvironment creates an extensive barrier toward the 
trafficking and distribution of nano-sized molecules. This barrier may limit the access of 
active targeting liposomes to a very limited number of cancer cells in solid tumors and 
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therefore reduce any therapeutic benefit relative to passively 
targeting liposome. The microregional intratumoral distribu-
tion of nano-sized liposomes has been illustrated to primarily 
be in the extracellular compartment adjacent to functional 
tumor blood vessels, which indicate that the proportion of 
cancer cells in direct contact with liposomes may be limited.7 
This observation is further complicated by the existence of 
disorganized tumor vasculature and intervascular distance 
and highly therapy-resistant hypoxic tumor regions.8 Active 
targeting of liposome formulations may additionally make 
them more prone to recognition by the reticuloendothelial 
system (RES) thereby altering the circulating properties and 
reducing liposome availability for tumor accumulation.3,9 
Despite the theoretical potential of active targeting liposomes 
the described obstacles may directly hinder the translation 
of in vitro efficacy to in vivo tumor models.
In the present study, we investigated the biodistribution 
and tumor-targeting potential of folate-targeting liposomes 
(FTLs). This was achieved using a highly flexible radiola-
beled liposome platform, which was applied for somatostatin 
receptor targeting liposomes in human neuroendocrine cancer 
xenografts.10 Folate receptors (FRs) are highly expressed on 
a wide spectrum of cancers, including ovarian, lung, brain, 
head and neck, renal cell, and breast cancers and display 
relatively low expression on nontumorous tissues with the 
main exception being inflamed tissue.11,12 Importantly, FRs 
mediate endocytosis to nonlysosomal endosomal vesicles 
and therefore provides an attractive therapeutic target for 
intracellular liposomal drug delivery.13 The use of radiola-
beled nontargeting liposomes (NTLs), radiolabeled FTLs, 
and functional positron emission tomography (PET) imag-
ing combined with computed tomography (CT) allows for 
quantification of biodistribution and tumor accumulation 
levels of both formulations.
Previous studies evaluating the therapeutic potential 
of FTL drug delivery systems are limited and results are 
conflicting in regards to therapeutic advantage for intra-
venously administered formulations.4,6,14–16 In comparison, 
intraperitoneal administration to ascites cancer models have 
improved the therapeutic efficacy of FTLs in comparison to 
NTLs. Thus, FTLs have potential, but this may require very 
directly accessible cancer cells.4,17 FTLs has been shown to 
be selectively taken up in the liver via receptor-mediated 
endocytosis in hepatic macrophages and display increased 
blood clearance relative to NTLs.9 Admistrating folic acid 
in mice intravenously or intraperitonealy has been shown 
to reduce hepatic uptake and increase circulating properties 
of liposomes, folate-targeting imaging agents, and folate-
targeting liposomes.9,11
The current study was conducted in two stages; first, the 
biodistribution of copper-64 radiolabeled FTLs (64Cu-FTLs) 
was compared to copper-64 radiolabeled NTLs (64Cu-NTLs) 
in mice bearing subcutaneous folate expressing KB-cell 
xenografts, and second, the effect of intravenous excess 
folic acid or vehicle on tumor uptake and biodistribution was 
compared for radiolabeled FTLs and NTLs.
Methods
Preparation of 64cu-radiolabeled FTls 
and NTls
Preparation of nontargeted liposomes
NTLs entrapping the high-affinity copper chelator, DOTA, 
were prepared. Briefly, 50 mg/mL freeze-dried lipid powder 
(HSPC:Chol:DSPE-PEG2k 56.5:38.2:5.3, Lipoid) was 
dispersed in a buffer containing 10 mM DOTA, 10 mM 
HEPES, and 150 mM NaCl (pH 7.4). The lipid suspension 
was hydrated for 60 minutes at 65°C and subsequently sized 
to 100 nm using a Lipex thermo barrel extruder (Northern 
lipids). The nonencapsulated DOTA was removed by tangen-
tial flow filtration (Minimate™, Pall Corporation).
Preparation of FTls
FTLs were prepared by postinsertion of 0.5 mol% DSPE-
PEG5k-folate into NTLs containing DOTA. Briefly, 1.7 mL 
NTLs (9.4 mM lipid) was added to 0.5 mg freeze-dried DSPE-
PEG5k-Folate powder, incubated for 20 minutes at 45°C with 
gentle shaking, then cooled on an ice bath, and checked for 
precipitates. The folate concentration was determined by 
UV-vis. Samples were diluted 1:9 in 10% SDS solution and 
incubated for 30 minutes at 60°C. Absorbance was measured 
at 282 nm and the folate concentration was determined via 
the molar extinction coefficient of DSPE-PEG5k-Folate 
27,500 M−1cm−1 using the absorbance of NTLs as a reference. 
The liposome size and zeta potential were verified by DLS 
(ZetaPALS Brookhaven) and the lipid concentration was 
determined by ICP-MS (iCAP Q, Thermo Scientific). NTLs 
were produced having an average size of 110 nm (polydisper-
sity index=0.07) and a zeta potential of −5±1 mV. No change 
in size or zeta potential was determined for the FTLs upon 
post insertion of DSPE-PEG5k-Folate.
remote loading of 64cucl2 into NTls and FTls
A total of 3.3 mM liposomes were added to a vial contain-
ing dried 64CuCl
2
. The liposome sample was incubated for 
75 minutes at 65°C using constant stirring and then cooled 
to room temperature. The 64Cu loading efficiency was deter-
mined by radio-HPLC and radio-thin-layer chromatography.18 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
98
.2
16
 o
n 
15
-M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7649
Folate receptor targeting liposomes reduce intratumoral accumulation
The activity concentration was set to 60–75 MBq/mL cor-
responding to 12–15 MBq/animal at the time of injection.
animal tumor model
KB cells (human nasopharyngeal carcinoma cell line, 
CCL-17; known for overexpressing FRs19,20 were obtained 
from the American Type Culture Collection (ATCC, VA, 
USA). Cells were grown in monolayers in FFRPMI cul-
ture medium (modified RPMI without folic acid, vitamin 
B
12
, and phenol red) in a humidified atmosphere at 37°C 
containing 5% CO
2
. The media was supplemented with 
10% FBS, 2 mM l-glutamine, 1 mM sodium pyrovate, 
nonessential amino acids, 100 U/mL penicillin, and 
100 µg/mL streptomycin.
Six-week-old female, athymic nude mice (NMRI nu/nu, 
Taconic Europe, Borup, Denmark) were allowed to accli-
matize for 1 week before subcutaneous inoculation on both 
flanks with KB cancer cells (1.5×106 cells in 100 µL serum-
free media and Matrigel).
experimental setup
Tumor xenografts were allowed to grow for 10 (study part 1) 
and 14 days (study part 2) prior to imaging. In study part 1, 
animals were randomized into two groups to receive either; 
64Cu-FTLs (n=7) or 64Cu-NTLs (n=7). In study part 2, animals 
were randomized into four groups: group 1, 64Cu-FTLs 
preinjected with folic acid (n=8); group 2, 64Cu-FTLs pre-
injected with vehicle (n=8); group 3, 64Cu-NTLs preloaded 
pre-injected with folic acid (n=5); and group 4, 64Cu-NTLs 
preinjected with vehicle (n=7). All experimental procedures 
were approved by and conducted under the guidelines of The 
Danish Animal Experiments Inspectorate.
Imaging procedures
All animals were anesthetized with a sevoflurane gas mixture 
and anesthetized mice had a tail vein catheter position to 
ensure strict intravenous injection of all formulations. All 
mice received 3.3 mM of lipid. Two anesthetized mice were 
positioned side-by-side, separated by a 6 mm polystyrene 
block, on a heated platform for PET/CT imaging. PET/CT 
imaging was performed on a dedicated Inveon® small animal 
PET/CT system with CT-based PET image attenuation 
(Siemens Medical Systems, Malvern, PA, USA).
In study part 1, 64Cu-labelled FTLs (64Cu-FTLs) and 
64Cu-labelled NTLs (64Cu-NTL) were administered as a 
bolus injection performed simultaneously with the start 
of a 10-minute dynamic PET acquisition. Three PET/CT 
sessions were conducted; a 10-minute dynamic acquisition 
commencing simultaneously with the bolus injection of 
liposomes, 5-minute static PET scan 3 hours after injection, 
and a 15-minute static PET scan 24 hours after injection. 
Following all PET scans, the imaging platform was moved 
automatically into the CT-scanner for anatomical imaging. 
The 10-minute dynamic PET scan was reconstructed into 
10×3 seconds, 6×5 seconds, 4×30 seconds, and 7×1 minutes 
frames. PET scans were reconstructed using a maximum 
a posteriori (MAP) reconstruction algorithm (pixel size: 
0.815×0.815×0.796 mm) and attenuation correction was 
performed based on the corresponding CT scan.
For study part 2, mice were injected with 100 µg of folic 
acid (Sigma-Aldrich, St Louis, MO, USA) suspended in 
100 µL of isotonic bicarbonate solution or 100 µL of isotonic 
bicarbonate solution (vehicle) 2 minutes prior to infusing 
64Cu-FTLs or 64Cu-NTLs. Animals were allowed to cage rest 
until performing PET/CT scans. Scans were performed using 
the same PET/CT scanner and set up as study part 1.
Dynamic PET imaging was performed on two mice from 
groups 1, 2, and 4 using a MicroPET® Focus 120 (Siemens 
Medical Systems, Malvern, PA, USA). Mice were subse-
quently CT imaged using a MicroCAT-II system (Siemens 
Medical Systems, Malvern, PA, USA). The PET scan com-
menced simultaneously with the injection of 64Cu-labelled 
liposomes and dynamic images were collected for 2 hours. 
Only the static 24-hour PET/CT scans were performed for 
these mice. The 2-hour dynamic PET scans were reconstructed 
into 10×3 seconds, 6×5 seconds, 4×30 seconds, 7×1 minutes, 
and 22×5 minutes frames using a similar MAP reconstruction.
Image analysis
Image analysis was performed using commercially avail-
able Inveon software (Siemens Medical Systems, Malvern, 
PA, USA). Regions of interests (ROIs) were manually 
constructed based on the coregistered PET/CT images. The 
following ROIs were constructed: tumors (complete volume 
delineated), liver (multiple slices taking care to avoid the 
hilar region), spleen, muscle, and blood. Blood activity was 
estimated from a constructed volume of interest ROI cover-
ing the left ventricular lumen of the heart, except for the 
dynamically scanned mice from study part 2, where an ROI 
was placed in the abdominal aorta. ROIs in the left ventricle 
and abdominal aorta were subsequently segmented to only 
include the voxels displaying above 80% of maximum activ-
ity with the original ROI. Time-activity curves (TACs) were 
constructed based on the dynamic images.
statistical analysis
Statistical analysis was performed using Prism 5.0 software 
(GraphPad Software Inc., La Jolla, San Diego, CA, USA).
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Comparison between activity of 64Cu-FTLs and 64Cu-
NTLs in study part one was performed using unpaired t-test. 
For intergroup comparison between liposome activities in 
study part 2, one-way ANOVA with Tukey post hoc multiple 
comparison analysis was used. Data were tested to follow 
a normal distribution by Komolgorov-Smirnov test. Results 
reported mean±SEM (unless otherwise stated) and P,0.05 
were considered statistically significant.
Results
Tumor uptake of Fr-targeted and 
nontargeted radiolabeled liposomes
Tumor volume was compatible between groups display-
ing a mean size of 78.4±7.4 mm3. The PET 64Cu activity 
levels were determined as % injected dose per gram of 
tissue (%ID/g) for the PET scans performed 3 hours and 
24 hours postinjection (pi.). No tumor uptake was reported 
for the initial 10-minute dynamic PET scan. There was no 
statistical difference between mean and maximum activity 
between 64Cu-FTLs (2.6%±0.3%ID/g and 5.6%±0.5%ID/g) 
and 64Cu-NTLs (2.5%±0.2%ID/g and 5.7%±0.4%ID/g) at 
3 hours pi. (unpaired t-test) (Figure 1A). However, 64Cu-
FTLs displayed a statistically significant lower tumor-to-liver 
ratio compared with 64Cu-NTLs (P=0.0052). No difference 
between mean tumor-to-blood or tumor-to-spleen ratios was 
observed between groups (Figure 1B).
At the PET scan 24 hours pi., 64Cu-NTLs displayed 
a statistically significant higher mean (7.8%±0.5%ID/g) 
and maximum (18.2%±1.5%ID/g) tumor activity in 
comparison to the mean (5.9%±0.6%ID/g) and maximum 
(13.4%±1.0%ID/g) tumor activity of 64Cu-FTLs (P=0.025 
and P=0.011) (Figure 1A). Mean tumor-to-blood ratio was 
statistically higher and tumor-to-liver ratio statistically lower 
for the 64Cu-NTLs compared to 64Cu-FTLs (P=0.005 and 
P=0.001), whereas tumor-to-spleen ratio was compatible 
between groups (Figure 1B). This reflects the increased 
liver uptake and the decreased circulating half-life of 
64Cu-FTLs.
Biodistribution and uptake kinetics of 
FTls and NTls
Mean liver activity of 64Cu-FTLs was statistically higher 
than 64Cu-NTLs 3 hours pi. (18.2%±0.5%ID/g and 
11.5%±0.7%ID/g, respectively, P,0.0001) and at 24 hours pi. 
(24.4%±1.2%ID/g and 10.3±0.7, respectively, P,0.0001). No 
difference was observed for mean activity in the blood between 
64Cu-FTLs and 64Cu-NTLs 3 hours pi. (28.7%±1.3%ID/g and 
29.6%±1.7%ID/g, respectively). However, 24 hours pi. activ-
ity of 64Cu-FTLs was significantly lower than 64Cu-NTLs 
(4.9%±0.3%ID/g and 9.1%±1.0%ID/g, P=0.001). On the 
contrary, splenic uptake of 64Cu-FTLs was significantly 
lower 24 hours pi. relative to 64Cu-NTLs (8.5%±0.6%ID/g 
and 12.3%±1.5%ID/g, respectively, P=0.032), whereas 
no significant difference was observed for mean activity 3 
hours pi. (10.4%±0.4%ID/g and 13.2%±1.5%ID/g, respec-
tively). However, the potential influence of blood volume 
in the spleen and the difference observed in blood activity 
24 hours pi., must be taken into consideration and differences 
Figure 1 accumulation of FTl and NTl in tumors.
Notes: (A) PeT tumor activity of 64cu-FTls and 64cu-NTls 3 hours pi and 24 hours pi in tumors. asterisks indicate statistically different means between mean and maximum 
activity of 64cu-FTls and 64cu-NTls (*P=0.025, **P=0.011, unpaired student’s t-test). (B) Tumor (T) to blood (B), liver (l), and spleen (s) activity ratios of 64cu-FTls and 
64cu-NTls 3 hours pi. and 24 hours pi. (*P=0.0052, **P=0.005, ***P=0.001, unpaired student’s t-test, bars represent mean %ID/g±seM).
Abbreviations: NTl, nontargeting liposomes; FTl, folate-targeting liposomes; seM, standard error of mean; pi., postinjection.
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can probably not solely be attributed to splenic uptake. No 
difference was observed for uptake levels in muscle 3 in 24 
hours pi. (Figures 2A and 3).
Dynamic uptake of the liposomal formulation was deter-
mined from the initial dynamic PET scan and scans 3 and 
24 hours pi. (Figure 2B). TACs illustrate the increased blood 
clearance and hepatic accumulation of 64Cu-FTLs relative to 
64Cu-NTLs (Figure 2B and C). Interestingly, splenic TAC 
illustrates the higher activity of 64Cu-NTLs rather 64Cu-FTLs 
24 hours pi. (Figure 2D). However, constructing a TAC of the 
spleen-to-blood ratio reverses this observation, which could 
indicate that the observed difference could be attributed to the 
higher activity of 64Cu-NTLs in the blood (Figure 2E).
Tumor uptake of FTls after folic acid 
coadministration
Tumor volume was compatible between the four groups of 
mice in the study part 2 (119.6±12.9 mm3), although slightly 
larger than the mean tumor volume of the tumors in study 
part 1 following a longer growth period. No difference in 
mean tumor activity between the group receiving excess folic 
acid or vehicle and 64Cu-FTLs or 64Cu-NTLs was observed 
3 hours pi. (Figure 4A). However, 24 hours pi., tumors in 
both 64Cu-NTLs groups display a higher mean and maximum 
activity of radiolabeled liposomes relative to groups receiving 
64Cu-FTLs (P,0.0001). Treatment with folic acid or vehicle 
mediated no change in tumor uptake between the 64Cu-FTLs 
groups or between the folic acid and vehicle 64Cu-NTLs mice 
(Figure 4A).
effect of coadministration of excess 
folic acid on biodistribution and uptake 
kinetics of FTls and NTls
The coadministration of excess folic acid reduced the mean 
liver activity of 64Cu-FTLs 3 hours pi. to 12.85%±0.9%ID/g, 
which was not statistically higher than the folic acid 
(11.7%±0.9%ID/g) and vehicle (11.3%±0.4%ID/g) treated 
64Cu-NTLs mice. Liver activity in 64Cu-FTLs mice receiving 
vehicle was significantly higher (18.3%±1.6%ID/g) 
compared to all other groups (P=0.0005). However, the 
Figure 2 Biodistribution of FTls and NTls.
Notes: (A) Biodistribution of 64cu-FTls and 64cu-NTls 3 hours pi. and 24 hours pi. asterisks indicate statistically different means between the mean and maximum activity 
of 64cu-FTls and 64cu-NTls (bars represent mean %ID/g±seM). (B–D) Tac of blood (B), liver (C), and spleen. (D) activity of 64cu-FTls and 64cu-NTls during a 10-minute 
dynamic PeT scan immediately after injection and static 3 hours and 24 hours pi. scans (mean±seM). (E) Tac of spleen-to-blood ratios for 64cu-FTls and 64cu-NTls during 
the initial 10-minute dynamic PeT scan and static 3 hours and 24 hours pi. scans (mean±seM, *P=0.032, **P=0.001, ***P,0.00001, unpaired student’s t-test).
Abbreviations: NTl, nontargeting liposomes; FTl, folate-targeting liposomes; Tac, time-activity curves; PeT, positron emission tomography; seM, standard error of mean.
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effect of excess folic acid on liver uptake was no longer 
evident 24 hours pi., where mean liver activity of 64Cu-
FTLs in the folic acid (19.3%±0.9%ID/g) and vehicle 
group (22.4%±1.1%ID/g) was no longer significantly dif-
ferent and both were significantly higher than 64Cu-NTLs 
in the folic acid (11.6%±0.6%ID/g) and vehicle group 
(11.2%±0.8%ID/g) (P,0.0001) (Figure 4B). Addition-
ally, liver activities during the first 120 minutes pi. of FTLs 
coadministered with folic acid resembled NTLs administered 
with a vehicle while FTLs with vehicle displayed higher liver 
activity (Figure 4C).
Blood activity of radiolabeled liposomes was not sta-
tistically different between groups 3 hours pi. The blood 
activity levels 24 hours pi. were statistically lower in both 
64Cu-FTLs groups (folic acid; 2.8%±0.3%ID/g and vehicle; 
2.8%±0.3%ID/g) in comparison to 64Cu-NTLs (folic acid; 
6.1%±0.4%ID/g and vehicle; 6.3%±0.2%ID/g) (P,0.0001). 
The activity of radiolabeled liposomes in the spleen was not 
statistically different between any of the groups 3 hours pi. 
nor 24 hours pi. (Figure 4B).
Dynamic PET scanning was performed to evaluate the 
influence of coadministration of excess folic acid on the 
initial liver uptake of mice receiving 64Cu-FTLs and excess 
folic acid or vehicle and 64Cu-NTLs plus vehicle. Com-
parison of the liver TAC indicates that coadministration 
of excess folic acid delays the initial liver activity of 64Cu-
FTLs to a level comparable to 64Cu-NTLs. However, after 
the first-hour uptake rate increases to a level comparable 
to that of 64Cu-FTLs vehicle-treated mice. TACs are based 
on only two mice in each group and they must be carefully 
interpreted.
Discussion
Despite the generally positive effects of FTLs in vitro, studies 
conducted in vivo have failed to yield compatible improved 
efficacy. This limited success of intravenously administered 
Figure 3 PeT/cT of FTls and NTls in tumor-bearing mice.
Notes: (A) 64cu-liposome PeT/cT images of 64cu-FTls 10 minutes, 3 hours, and 24 hours pi. (top images) and 64cu-NTls 10 minutes, 3 hours, and 24 hours pi. (bottom 
images). liver (l), spleen (arrow). (B) 64cu-liposome PeT images 24 hours pi. of tumor uptake of 64cu-FTls (top image) and 64Cu-NTLs (bottom image). Left and right flank 
tumors are encircled in white, liver (l), spleen (arrow).
Abbreviations: FTl, folate-targeting liposomes; NTl, nontargeting liposomes; PeT/cT, positron emission tomography/computed tomography.
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liposome formulations targeting FRs was the basis for the 
present study, which aimed to provide direct quantitative 
information on tumor accumulation and circulating char-
acteristics of FTLs by high sensitive and quantitative PET 
imaging.4,6,21
The presented data illustrate the impact of the reduced 
circulating half-life of FTLs on tumor accumulation and that 
actively targeting FRs, highly expressed on cancer cells, does 
not improve overall delivery. FTLs were rapidly taken up in 
the liver which was already observable 3 hours pi. The high 
level of liver uptake has previously been reported for both 
FTLs and folate-targeting imaging agents.9,11
This study was conducted on relatively small solid 
tumors. This was based on the previously reported improved 
therapeutic efficacy of encapsulated doxorubicin in FTLs in 
comparison to NTLs in small KB xenografts inoculated in 
the footpad of mice,4 which suggested a potential targeting 
possibility in small tumors. The larger tumors in the second 
part of the study displayed slightly lower mean tumor uptake, 
supporting previous reports of lower EPR-based liposome 
uptake with increasing tumor size.22
Although a folate-restricted diet might be expected 
to boost FR expression, it has been shown not to influ-
ence folate binding of KB xenografts and M109 tumors in 
mice9, and thus this study was conducted without feeding 
mice folate-restricted diets. Additionally, low-folate diets 
were shown to increase tissue retention of folate-targeted 
radiopharmaceuticals23,24 which would further deplete cir-
culating FTLs.
The effect of blocking uptake by liver by coadminister-
ing excess folic acid to improve the circulating properties 
of FTLs was investigated. This approach has been identified 
to decrease uptake in liver and other tissues expressing high 
levels of FRs11 and a similar folate preinjection approach has 
Figure 4 Biodistribution of FTls and NTls in competition with folic acid.
Notes: (A) PeT tumor activity of 64cu-FTls and 64cu-NTls with folic acid or vehicle coadministration 3 hours pi. and 24 hours pi. Tumor mean and maximum activity was 
statistically higher for 64cu-NTl in comparison to 64cu-FTl independent of administration of folic acid (#P=0.0005 and *P,0.0001). (B) Biodistribution of 64cu-FTls and 
64cu-NTls with folic acid or vehicle coadministration 3 hours pi. and 24 hours pi. Folic acid predosing was able to reduce early (3 hours pi.) mean liver activity of 64cu-FTl to 
the level of 64cu-NTl liver activity. The liver activity of vehicle administered 64Cu-FTL was significantly higher than 64cu-NTl (vehicle and folic acid predosed) and folic acid 
predosed 64cu-FTl (**P,0.01). Independent of folic acid or vehicle predosing the blood mean activity 24 hours pi. was significantly higher for 64cu-NTl in comparison to the 
both 64cu-FTl groups (##P,0.0001). at 24 hours pi. mean liver activity of both folic acid and vehicle predosed 64Cu-FTL groups was significantly higher than 64cu-NTl groups 
independent of predosing (##P,0.0001). (C) 2-hour dynamic liver activity (%ID/g) of 64cu-FTl and folic acid predosing (n=2) or vehicle (n=2) and 64cu-NTl and vehicle (n=2) 
on PeT scans commencing simultaneously with the injection of radiolabeled liposomes (bars represent mean %ID/g±seM. all comparisons were performed using one-way 
aNOVa analysis and post hoc Tukey multiple comparison analysis).
Abbreviations: FTl, folate-targeting liposomes; NTl, nontargeting liposomes; PeT, positron emission tomography; seM, standard error of mean; pi., postinjection.
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been safely performed in human ovarian and endometrial 
cancer patients.25 Thus, intravenous preinjection of excess 
folate had acceptable translational potential and was chosen 
over the intraperitoneal administration of very high doses of 
folic acid, which may result in a more prolonged blockade 
of hepatic receptors.24 A preinjection of excess folic acid 
has, additionally, been shown to decrease tumor accumula-
tion of folate-targeting radiotracers11,26 and may have no 
effect on liposome accumulation in tumor.9 In this study, 
the results of folic acid coadministration demonstrate no 
difference between FTLs and NTLs uptake levels in tumors 
of mice pretreated with folic acid or vehicle. Liver uptake 
was only significantly reduced in folic acid injected mice in 
the 3 hours PET scan, indicating that the blockade is short 
lived and insufficient for liposomes with long-circulating 
half-lives. To increase the circulating half-life of FTLs, 
multiple doses or long-acting folic acid may be needed 
which, following the reported blockade of tumor cell recep-
tors by the excess folic acid administration, could directly 
inhibit the cancer cell-targeting strategy. Importantly, the 
influence of folate-mediated liver uptake in humans injected 
with FTLs remains to be determined. However, the liver is 
the primary storage organ for folate and FRs are expressed 
by activated human macrophages. Macrophage-mediated 
uptake and elimination may therefore also be an important 
issue for circulatory properties in humans.27–29 Alternatively, 
administration of antifolates (eg, pemetrexed) has been per-
formed in conjunction with FR-targeting agents and shown 
to decrease renal uptake without affecting tumor uptake.30 
Administration of pemetrexed may, however, be associated 
with unwanted side effects, especially in patients already 
undergoing chemotherapy.
The results of this study indicate that the EPR effect and 
circulating properties of liposome formulations determine the 
liposome levels that may be achieved, independently of active 
tumor cell receptor targeting. This statement is supported 
by the previously observed reduced, but more compatible, 
uptake levels of somatostatin receptor targeting liposomes 
relative to NTLs.10
The results demonstrate that the active targeting of FRs 
on human cancer cells with known high expression decreases 
the overall liposome uptake within solid tumor xenografts. 
Thus, drug delivery by liposomes targeting FRs signifi-
cantly decrease the total amount of liposomes delivered to 
solid tumors. It is therefore of key importance to include a 
nontargeting liposomal comparator when evaluating anti-
cancer therapy based on targeting liposomes if statements 
on the improved efficiency of active targeting are to be 
valid. Despite the lack of valid comparators, FTLs have 
been purported to provide improved therapeutic efficacy 
based on their targeting properties although this effect is 
primarily attributable to an EPR-based improved drug deliv-
ery within tumors.31
The presented data do not provide information on the 
uptake levels achieved in single cancer cells within the solid 
tumor mass between targeting and NTLs. Several studies 
and reviews highlight the increased cellular uptake by active 
targeting as a method to increase the amount of drug delivered 
and thus improve the therapeutic efficacy.3
This consideration might be attractive if all cells within 
solid tumors were readily accessible for nano-sized particles. 
However this does not seem to be the case.7 Active targeting 
to the more readily available neo-angiogenic tumor vascula-
ture is far more appealing. Several attractive vascular targets 
are probably directly accessible to circulating liposomes 
and could allow accumulation and subsequent triggered 
drug release within the vasculature to increase loco-regional 
drug concentration.32,33 FTLs may have therapeutic potential 
beyond the direct targeting of FR expressing cancer cells 
as important associations between tumor-associated mac-
rophages (TAMs) expressing FR-β and malignant charac-
teristics has been identified. TAMs play prominent roles in 
angiogenesis, cancer cell invasion, and extravasation. FR-β 
expressing TAM has additionally been shown to mediate 
potent immunosuppressive functions.34–36 Importantly, with 
respect to the perivascular accumulation liposomes, the 
TAMs reside in the perivascular compartment thus making 
them potential targets that could be reached by FTLs.34,37 The 
majority FR-β expressing TAM in human pancreatic cancer 
has additionally been shown to express vascular endothelial 
growth factor which increases vascular permeability and 
therefore potentially improved liposome extravasation to 
perivascular areas harboring FR-β TAMs.34,38
Notwithstanding the challenges faced EPR-based lipo-
some accumulation in solid cancer remains an attractive 
methodology for drug delivery, however, achieving improved 
targeting and triggered release within the accessible extracel-
lular compartments remain an important goal.
Directly targeting specific cancer cell receptors, including 
FRs, has proven successful in numerous in vitro studies.39–42 
Varying therapeutic effects of FR-targeting in tumor models 
has been observed in in vivo studies, ranging from promis-
ing to discouraging results4,6,14,15,43,44 However, other in vivo 
studies has also, in agreement with the current study, targeted 
FR with liposomes with poor tumor accumulation compared 
to controls.9,12,45 Although results by previous studies are 
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somewhat contradicting, it may be partly explained by differ-
ences in tumor models, formulations, and other experimental 
details and, as previously stated, be partly explained by 
differences in cellular uptake. Previous in vivo studies have 
mainly used 3H- or fluorophore-imaging to assess biodistri-
bution while the current study included PET/CT imaging 
to obtain more dynamic and sensitive results. Furthermore, 
this study demonstrates the importance of in vivo studies to 
demonstrate the actual targeting potential.
In conclusion, targeting FRs provided no improvement 
of the overall liposome delivery to solid KB xenografts 
determined by PET. Although only FTLs were included 
in the present study. It clearly demonstrates that surface 
modifications to liposomes must be carefully evaluated as 
this may significantly influence the circulation and biodis-
tribution. Any observed improved in vitro cytotoxic efficacy 
must, therefore, be carefully evaluated as this improved 
effect, in comparison to long-circulating controls, can easily 
be lost following significant difference in EPR-dependent 
tumor accumulation. Further studies are warranted to fully 
elucidate the potential of various ligands targeting cancer 
cell receptors and subsequent intratumoral microregional 
distribution. Importantly, the present study was conducted 
in a murine xenograft model, which may display a far less 
complicated tumor environment than clinical cancers and 
therefore potentially illustrate the problems targeted drug 
delivery systems faced in clinical cancers. The targeting and 
therapeutic potential of FTLs may benefit from investigations 
in additional animal models with a folate metabolism that 
better simulate human folate metabolism to elucidate their 
and therapeutic potential fully.
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